Vol 8, No 4 (2017)
Review paper
Published online: 2018-02-24
The role of hematopoietic stem cell transplantation in the treatment of patients with primary cutaneous lymphomas
Hematologia 2017;8(4):280-288.
Abstract
Primary cutaneous lymphomas are heterogeneous group of lymphoid neoplasms, mostly of T-cell origin; the primary proliferation being confined only to the skin. Cutaneous lymphomas usually run an indolent course but are rarely curable, particularly in advanced stages. Various treatments are adopted: surgery, chemotherapy and radiotherapy. Hematopoietic stem cell transplantation is used very rarely in treatment strategies. Indications for selecting any of such treatments are mostly based on expert opinion and limited clinical data, and they differ depending on histopathological subtype.
Keywords: primary cutaneous lymphomahematopoietic stem cell transplantationsystemic treatment
References
- Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768–3785.
- Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of hematopoietic and lymphoid tissues. IARC. 2008: 179–317.
- van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol. 2000; 136(4): 504–510.
- Sokołowska-Wojdyło M, Lech-Marańda E, Placek W, et al. w imieniu Polskiej Grupy Badawczej Chłoniaków. Leczenie pierwotnych chłoniaków skóry. Rekomendacje Sekcji Chłoniaków Skóry Polskiej Grupy Badawczej Chłoniaków (PLRG). Onkol Prak Klin. 2010; 6(1): 29–47.
- Fierro MT, Quaglino P, Savoia P, et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998; 31(5-6): 583–588.
- Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86(7): 1368–1376, doi: 10.1002/(sici)1097-0142(19991001)86:7<1368::aid-cncr37>3.3.co;2-#.
- Mebazaa A, Dupuy A, Rybojad M, et al. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Hematol J. 2005; 5(7): 553–558.
- Bigler RD, Crilley P, Micaily B, et al. Autologous bone marrow transplantation for advanced stage mycosis fungoides. Bone Marrow Transplant. 1991; 7(2): 133–137.
- Olavarria E, Child F, Woolford A, et al. T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement. Br J Haematol. 2001; 114(3): 624–631.
- Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008; 41(7): 597–604.
- Goldstein SC, Porter DL. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies. Expert Rev Hematol. 2010; 3(3): 301–314.
- Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005; 23(25): 6163–6171.
- Delioukina M, Zain J, Palmer JM, et al. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant. 2012; 47(1): 65–72.
- Paralkar VR, Nasta SD, Morrissey K, et al. Allogeneic hematopoietic SCT for primary cutaneous T cell lymphomas. Bone Marrow Transplant. 2012; 47(7): 940–945.
- Duvic M, Donato M, Dabaja B, et al. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010; 28(14): 2365–2372.
- Duarte RF, Boumendil A, Onida F, et al. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis. J Clin Oncol. 2014; 32(29): 3347–3348.
- Lechowicz MJ, Lazarus HM, Carreras J, et al. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014; 49(11): 1360–1365.
- Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood. 2016; 127(25): 3142–3153.
- Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. 1991; 325(15): 1078–1081.
- Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003; 101(9): 3407–3412.
- de Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity? Histopathology. 2000; 36(4): 294–305.
- Fijnheer R, Sanders CJG, Canninga MR, et al. Complete remission of a radiochemotherapy-resistant cutaneous T-cell lymphoma with allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant. 2003; 32(3): 345–347.
- Pérez-Persona E, Mateos-Mazón JJ, López-Villar O, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplant. 2006; 38(12): 821–822.
- Zenahlik P, Fink-Puches R, Kapp KS, et al. [Therapy of primary cutaneous B-cell lymphomas]. Hautarzt. 2000; 51(1): 19–24.
- Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases. Radiother Oncol. 1999; 52(1): 15–18.
- Kütting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997; 36(2 Pt 2): 311–314.
